|
[1]BOONSTRA K,BEUERS U,PONSIOEN CY.Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis:a systematic review[J].J Hepatol,2012,56(5):1181-1188.
|
|
[2]CAREY EJ,ALI AH,LINDOR KD.Primary biliary cirrhosis[J].Lancet,2015,386(10003):1565-1575.
|
|
[3]MAYO MJ.Natural history of primary biliary cirrhosis[J].Clin Liver Dis,2008,12(2):277-288.
|
|
[4]PRINCE M,CHETWYND A,NEWMAN W,et al.Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis:follow-up for up to 28 years[J].Gastroenterology,2002,123(4):1044-1051.
|
|
[5]Chinese Society of Hepatology,Chinese Medical Association;Chinese Society of Gastroenterology,Chinese Medical Association;Chinese Society of Infectious Diseases,Chinese Medical Association.Consensus on the diagnosis and management of primary biliary cirrhosis(cholangitis)(2015)[J].J Clin Hepatol,2015,31(12):1980-1988.(in Chinese)中华医学会肝病学分会,中华医学会消化病学分会,中华医学会感染病学分会.原发性胆汁性肝硬化(又名原发性胆汁性胆管炎)诊断和治疗共识(2015)[J].临床肝胆病杂志,2015,31(12):1980-1988.
|
|
[6]INVERNIZZI P,PODDA M,BATTEZZATI PM,et al.Autoantibodies against nuclear pore complexes are associated with more active and severe liver disease in primary biliary cirrhosis[J].J Hepatol,2001,34(3):366-372.
|
|
[7]NAKAMURA M,KONDO H,MORI T,et al.Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis[J].Hepatology,2007,45(1):118-127.
|
|
[8]LUDWIG J,DICKSON ER,McD ONALD GS.Staging of chronic nonsuppurative destructive cholangitis(syndrome of primary biliary cirrhosis)[J].Virchows Arch A Pathol Anat Histol,1978,379(2):103-112.
|
|
[9]YOU Z,WANG Q,BIAN Z,et al.The immunopathology of liver granulomas in primary biliary cirrhosis[J].J Autoimmun,2012,39(3):216-221.
|
|
[10]POUPON RE,LINDOR KD,CAUCHDUDEK K,et al.Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis[J].Gastroenterology,1997,113(3):884-890.
|
|
[11]ANGULO P,BATTS KP,THERNEAU TM,et al.Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis[J].Hepatology,1999,29(3):644-647.
|
|
[12]IMAM MH,LINDOR KD.The natural history of primary biliary cirrhosis[J].Semin Liver Dis,2014,34(3):329-333.
|
|
[13]POUPON RE,BONNAND AM,CHRETIEN Y,et al.Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis[J].Hepatology,1999,29(6):1668-1671.
|
|
[14]ALI AH,CAREY EJ,LINDOR KD.The management of autoimmunity in patients with cholestatic liver diseases[J].Expert Rev Gastroenterol Hepatol,2016,10(1):73-91.
|
|
[15]PARES A,CABALLERIA L,RODES J.Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid[J].Gastroenterology,2006,130(3):715-720.
|
|
[16]TRIVEDI PJ,LAMMERS WJ,van BUUREN HR,et al.Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis:a multicentre international study[J].Gut,2016,65(2):321-329.
|
|
[17]CORPECHOT C,ABENAVOLI L,RABAHI N,et al.Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis[J].Hepatology,2008,48(3):871-877.
|
|
[18]LAMMERS WJ,HIRSCHFIELD GM,CORPECHOT C,et al.Development and validation of a scoring system to predict outcomes o patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy[J].Gastroenterology,2015,149(7):1804-1812.
|
|
[19]NAKAI S,MASAKI T,KUROKOHCHI K,et al.Combination therapy of bezafibrate and ursodeoxycholic acid in primary biliary cirrhosis:a preliminary study[J].Am J Gastroenterol,2000,95(1):326-327.
|
|
[20]KURIHARA T,NIIMI A,MAEDA A,et al.Bezafibrate in the treatment of primary biliary cirrhosis:comparison with ursodeoxycholic acid[J].Am J Gastroenterol,2000,95(10):2990-2992.
|
|
[21]HAN XF,WANG QX,LIU Y,et al.Efficacy of fenofibrate in Chinese patients with primary biliary cirrhosis partially responding to ursodeoxycholic acid therapy[J].J Dig Dis,2012,13(4):219-224.
|
|
[22]ZHANG Y,LI S,HE L,et al.Combination therapy of fenofibrate and ursodeoxycholic acid in patients with primary biliary cirrhosis who respond incompletely to UDCA monotherapy:a meta-analysis[J].Drug Des Devel Ther,2015,9:2757-2766.
|
|
[23]YIN Q,LI J,XIA Y,et al.Systematic review and meta-analysis:bezafibrate in patients with primary biliary cirrhosis[J].Drug Des Devel T-her,2015,9:5407-5419.
|
|
[24]LEUSCHNER M,MAIER KP,SCHLICHTING J,et al.Ora budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis:results of a prospective double-blind trial[J].Gastroenterology,1999,117(4):918-925.
|
|
[25]ANGULO P,JORGENSEN RA,KEACH JC,et al.Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptima response to ursodeoxycholic acid[J].Hepatology,2000,31(2):318-323.
|
|
[26]RAUTIAINEN H,KARKKAINEN P,KARVONEN AL,et al.Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis:a three-year randomized trial[J].Hepatology,2005,41(4):747-752.
|
|
[27]RAUTIAINEN H,FARKKILA M,NEUVONEN M,et al.Pharmacokinetics and bone effects of budesonide in primary biliary cirrhosis[J].Aliment Pharmacol Ther,2006,24(11-12):1545-1552.
|
|
[28]HEMPFLING W,DILGER K,REICHEL C,et al.Pharmacokinetics and pharmacodynamic action of budesonide in early-and latestage primary biliary cirrhosis[J].Hepatology,2003,38(1):196-202.
|
|
[29]FANG YQ,LV DX,JIA W,et al.Case-control study on prednisolone combined with ursodeoxycholic acid and azathioprine in pure primary biliary cirrhosis with high levels of immunoglobulin G and transaminases efficacy and safety analysis[J].Medicine,2014,93(20):e104.
|
|
[30]RABAHI N,CHRETIEN Y,GAOUAR F,et al.Triple therapy with ursodeoxycholic acid,budesonide and mycophenolate mofetil in patients with features of severe primary biliary cirrhosis not responding to ursodeoxycholic acid alone[J].Gastroenterol Clin Biol,2010,34(4-5):283-287.
|
|
[31]POUPON R.Evidence-based treatment of primary biliary cirrhosis[J].Dig Dis,2014,32(5):626-630.
|
|
[32]COMBES B,EMERSON SS,FLYE NL,et al.Methotrexate(MTX)plus ursodeoxycholic acid(UDCA)in the treatment of primary biliary cirrhosis[J].Hepatology,2005,42(5):1184-1193.
|
|
[33]KAPLAN MM,BONDER A,RUTHAZER R,et al.Methotrexate in patients with primary biliary cirrhosis who respond incompletely to treatment with ursodeoxycholic acid[J]Dig Dis Sci,2010,55(11):3207-3217.
|
|
[34]GILJACA V,POROPAT G,STIMAC D,et al.Methotrexate for primary biliary cirrhosis[J].Cochrane Database Syst Rev,2010,(5):CD004385.
|
|
[35]LOMBARD M,PORTMANN B,NEUBERGER J,et al.Cyclosporin A treatment in primary biliary cirrhosis:results of a long-term placebo controlled trial[J].Gastroenterology,1993,104(2):519-526.
|
|
[36]SHIBA H,WAKIYAMA S,FUTAGAWA Y,et al.Switching from tacrolimus to cyclosporine A to prevent primary biliary cirrhosis recurrence after living-donor liver transplantation[J].Int Surg,2013,98(2):156-159.
|
|
[37]PELLICCIARI R,FIORUCCI S,CAMAIONI E,et al.6 alphaethyl-chenodeoxycholic acid(6-ECDCA),a potent and selective FXR agonist endowed with anticholestatic activity[J].J Med Chem,2002,45(17):3569-3572.
|
|
[38]FIORUCCI S,RIZZO G,DONINI A,et al.Targeting farnesoid Xreceptor for liver and metabolic disorders[J].Trends Mol Med,2007,13(7):298-309.
|
|
[39]HIRSCHFIELD GM,MASON A,LUKETIC V,et al.Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid[J].Gastroenterology,2015,148(4):751-761.e8.
|
|
[40]KOWDLEY KV,JONES D,LUKETIC V,et al.An international study evaluating the farnesoid X receptor agonist obeticholic acid as monotherapy in PBC[J].J Hepatol,2011,54(9):s13.
|
|
[41]NEVENS F,ANDREONE P,MAZZELLA G,et al.The first primary biliary cirrhosis(PBC)phase 3 trial in two decades-an international study of the fxr agonist obeticholic acid in PBC patients[J].J Hepatol,2014,60(1):s525-s526.
|
|
[42]AVIVI I,STROOPINSKY D,KATZ T.Anti-CD20 monoclonal antibodies:beyond B-cells[J].Blood Rev,2013,27(5):217-223.
|
|
[43]MORITOKI Y,LIAN ZX,LINDOR K,et al.B-cell depletion with anti-CD20 ameliorates autoimmune cholangitis but exacerbates colitis in transforming growth factor-beta receptor II dominant negative mice[J].Hepatology,2009,50(6):1893-1903.
|
|
[44]TSUDA M,MORITOKI Y,LIAN ZX,et al.Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid[J].Hepatology,2012,55(2):512-521.
|
|
[45]MYERS RP,SWAIN MG,LEE SS,et al.B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid[J].Am J Gastroenterol,2013,108(6):933-941.
|
|
[46]TAJIRI K,TSUNEYAMA K,MIYAZONO T,et al.A case of primary biliary cirrhosis that progressed rapidly after treatment involving rituximab[J].Case Rep Gastroenterol,2013,7(1):195-201.
|
|
[47]JOPSON L,NEWTON JL,PALMER J,et al.RITPBC:B-cell depleting therapy(rituximab)as a treatment for fatigue in primary biliary cirrhosis:study protocol for a randomised controlled trial[J].BMJ Open,2015,5(8):e007985.
|
|
[48]MELLS GF,FLOYD JAB,MORLEY KI,et al.Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis[J].Nat Genet,2011,43(4):329-332.
|
|
[49]YOSHIDA K,YANG GX,ZHANG W,et al.Deletion of interleukin-12p40 suppresses autoimmune cholangitis in dominant negative transforming growth factor beta receptor type II mice[J].Hepatology,2009,50(5):1494-1500.
|
|
[50]HIRSCHFIELD GM,GERSHWIN ME,STRAUSS R,et al.Phase 2study evaluating the efficacy and safety of ustekinumab in patients with primary biliary cirrhosis who had an inadequate response to ursodeoxycholic acid[J].J Hepatol,2014,60(1):s189-s190.
|
|
[51]DHIRAPONG A,YANG GX,NADLER S,et al.Therapeutic effect of cytotoxic T lymphocyte antigen 4/immunoglobulin on a murine model of primary biliary cirrhosis[J].Hepatology,2013,57(2):708-715.
|
|
[52]MOUSA HS,LLEO A,INVERNIZZI P,et al.Advances in pharmacotherapy for primary biliary cirrhosis[J].Expert Opin Pharmacother,2015,16(5):633-643.
|
|
[53]WANG L,HAN Q,CHEN H,et al.Allogeneic bone marrow mesenchymal stem cell transplantation in patients with UDCA-resistant primary biliary cirrhosis[J].Stem Cells Dev,2014,23(20):2482-2489.
|
DownLoad: